Emerging antibiotic resistance against carbapenems is a serious issue and urgent measures are required to curb such development of resistance. There is paucity of data on the prevalence of carbapenem resistance in the Indian literature. This study involves a retrospective analysis of culture and sensitivity data on 174 clinical specimens obtained from different hospitals in Kanpur. Of the specimens, 15% grew bacilli which were resistant to at least one of the carbapenems. Of these bacilli 92% were resistant to Meropenem and sensitive to Imipenem. Only one specimen, that of urine grew E-coli which was resistant to Imipenem but sensitive to Meropenem. Staphylococcus aureus constituted majority (77%) of the resistant bacilli. E-coli were the second most common resistant bacilli to be isolated. Pseudomonas aeruginosa constituted 8%
Introduction antibiotics started emerging from 1990 and has been Nosocomial infection is a serious challenge as it repor ted worldwide over the years with varying increases significantly the morbidity and mortality, frequencies. [1] Pseudomonas aeruginosa besides, the high incidence of gram negative bacteria Acinetobacter spp. in particular are most often associated and development of multi-drug resistance still remains a with carbapenem resistance. There is paucity of data on serious problem. This has fueled the development and the prevalence of carbapenem resistance in the Indian addition of newer antibiotics to the armamentarium and literature, which is required for developing insight into Abstract and many guidelines for their use as well. Carbapenems first introduced in 1980 are now frequently used as a reserved drug in treating serious infection caused by multi-drug resistant gram negative bacilli. These antibiotics are stable to β-lactamases including the extended spectrum β-lactamases (ESBLs) and AmpC produced by gram negative bacilli. Unfortunately resistance to these management of serious nosocomial infections and measures for curbing the emergence of carbepenem resistance. [2, 3] This study involves a retrospective analysis of the culture and sensitivity data on specimens obtained from various hospitals in Kanpur city in an attempt to answer key questions: 1) what is the incidence of various organisms 2) incidence of organisms with respect to the type of specimen 3) incidence of Imipenem and diagnostic laboratory on specimens received over the past four months. Majority of specimens obtained were from private nursing homes and multi-specialty hospitals in and around Kanpur city. Many of these have intensive care set-up. Few specimens were also obtained from a large teaching hospital of the city. Samples with more than 24h of refrigeration were not processed. All specimens were inoculated on 5% sheep blood and MacConkey agar plates and incubated overnight at 37 0 C pneumoniae (6.9%), Proteus mirabilis (0.6%), Pseudomonas aeruginosa (8%), Staphylococcus aureus (31%) and Meningiococcus (0.6%).
Urine was the most common specimen. Of the urine specimens, 84% grew E-coli, 8.5% grew Klebsiella pneumoniae, 2% grew Pseudomonas aeruginosa and Staph aureus and 1% grew Citrobacter, Enterobacter and Proteus mirabilis. The second most common aerobically (MacConkey agar) and in 5% carbon dioxide specimen was pus, of which 75% grew Staphylococcus (blood agar). Bacterial pathogens were identified by aureus, 9% grew Pseudomonas aeruginosa, 11% grew conventional biochemical methods according to standard E-coli and 2% grew Citrobacter and Klebsiella microbiological techniques. [4] A sample was included in pneumoniae. Half of the central line catheter tip the study only if it was positive for less than two types of specimens grew Staphylococcus aureus, 36% of these bacteria. Antimicrobial sensitivity was performed on specimens grew Pseudomonas aeruginosa and 7% of Mueller-Hinton agar (Hi-Media, India) against Imipenem the specimens grew E-coli and Klebsiella pneumoniae.
(10 µg/disc) and Meropenem (10 µg/disc) by the standard Of the sputum samples, 71% grew Staph aureus, 21% disk diffusion method recommended by the National grew Pseudomonas aeruginosa and 7% grew E-coli. Of Committee for Clinical Laboratory Standards (NCCLS). [5] the Endo-tracheal tube aspirate E-coli, Klebsiella and The diameter of the zone of inhibition of growth was Staphylococcus aureus were grown with similar recorded and interpreted as susceptible or resistant by frequency (33%). There was only one specimen of CSF the criteria of NCCLS.
[5] Organisms with "intermediate" which grew Meningiococcus. levels of resistance were included in the percentage of resistant organisms for final analysis. The variables Carbapenem resistance profile of isolated organisms recorded were the specimen source, bacteria grown and is shown in Table 1 . Of the specimens, 15% grew resistance to Imipenem and Meropenem. The data was Carbapenem resistant bacilli. Of these bacilli 92% were analyzed using SPSS software (version 11, Chicago).
resistant to Meropenem and sensitive to Imipenem. Only one specimen, that of urine grew E-coli which was
Results
resistant to Imipenem but sensitive to Meropenem and 174 specimens were surveyed over the past two month just one specimen, that of sputum grew Staphylococcus period, 120 samples in the first two months had to be aureus which was resistant to both Imipenem and excluded to prevent methodology bias, as culture plates Meropenem. and antibiotic discs being used, were of different make. Type of specimens included central line catheter tip (8%), Staphylococcus aureus constituted majority (77%) of endo-tracheal tube aspirate (3.4%), pus (25.8%), sputum the resistant bacilli. Except one isolate which was (8%), urine (54%) and cerebrospinal fluid (CSF) (0.6%). resistant to both, all others were sensitive to Imipenem Overall eight organisms were isolated namely Citrobacter but resistant to Meropenem. Three fourths of these (1.2 %), E-coli (50.6%), Enterobacter (0.6%), Klebsiella resistant Staph were isolated from pus, 10% from sputum and urine and 5% from central line catheter tip.
E-coli were the second most common resistant bacilli to be isolated and constituted 12% (3) of the resistant bacilli. Two of these were sensitive to Imipenem but resistant to Meropenem and were isolated from pus, one isolate which was obtained from urine was resistant to Imipenem but sensitive to Meropenem.
The common form of resistance is mediated by lack of drug penetration (i.e., porin mutations and efflux pumps) and/or carbapenem-hydrolyzing -lactamses. Based on molecular studies, Carbapenem -hydrolyzing enzymes are classified into four groups A, B, C and D. The metallo betalactamases (MBLs) belong to group B and are enzymes requiring divalent cations as cofactors for enzyme activity, being inhibited by the action of a metal ion chelator. [10] Pseudomonas aeruginosa constituted 8% (2) of the resistant bacilli. Both of these were sensitive to Imipenem
The prevalence of resistance among Pseudomonas but resistant to Meropenem. One was isolated from aeruginosa (14%) was found to be similar to that reported central line catheter tip and other from urine.
in previous study in the Indian setup.
[11] However evidence of resistance amongst E. coli was found to be alarming Mengiococcus isolated once from a CSF specimen was as a recent study on 353 E. coli specimens failed to reveal sensitive to Imipenem but resistant to Meropenem.
resistance. [12] The mechanism behind selective resistance against Meropenem needs to be investigated.
Discussion
Measures to reduce antibiotic resistance include Carbapenems are one of the essential antibiotics in evidence-based selection of antibiotics, shorter courses the armamentarium against serious nosocomial of appropriately selected antibiotics with adequate infections. Development of resistance against these is a dosages, surveillance for resistance, prevention of cause of concern. Reasons behind such increase in the spread of resistant organisms, cyclical use if new incidence of resistance against carbapenems could be antibiotics become available, education of consumers several. Among physicians, fear of litigation and and prescribers about use and misuse of antibiotics, perception of patient's expectations contribute to development of new drugs to circumvent or blockantibiotic misuse and, therefore, bacterial resistance. It resistance mechanisms and revival of susceptible is possible that carbapenems are being used empirically. bacteria through more appropriate antibiotic use or potential use of probiotics. Steps need to be taken to It has been shown that inappropriate duration of prevent antimicrobial resistance or else this emerging antibiotic therapy also helps in development of menace would erode the strength of life-saving resistance. [6] Subtherapeutic concentrations of the drug antibiotics, leave them with the negligible effect of is another impor tant cause of development of placebo and put all significant resources allocated to resistance. [7] Carbapenems are often used for critically-research and treatment to waste in an already resource ill patients and it has been shown that the drug poor country like ours. concentrations in tissues achieved in these patients are often subtherapeutic in spite of standard dosages administered. [8] We found that incidence of resistance against Meropenem was more than Imipenem. Meropenem is well-tolerated and offers several potential advantages, including greater in vitro activity against Gram-negative pathogens and the option of bolus administration. [9] Besides these, problem of renal metabolism of Imipenem and risk of seizures and greater availability of Meropenem in the market might be the reasons behind possible greater use of Meropenem over Imipenem and hence the higher incidence of resistance. 
